LINC01002: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC01002

NCBI ID: G399844

LINC01002

Other Name(s): long intergenic non-protein coding RNA 1002 | Long intergenic non-protein coding RNA 1002

LINC01002: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC01002 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified as a potential drug target and biomarker. It is a non-coding RNA molecule that is expressed in a variety of tissues and cells, including the brain, heart, and gastrointestinal tract. LINC01002 has been shown to play a role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Drug Target Potential

LINC01002 has been identified as a potential drug target due to its unique structure and expression pattern. It is a long RNA molecule that is highly conserved in its sequence across different species. This conservation suggests that LINC01002 may have a similar function or structure in different organisms, which could make it an attractive target for small molecules or antibodies that can modulate its expression or activity.

In addition, LINC01002 has been shown to play a role in several cellular processes that are involved in disease development, such as cell signaling, cell division, and inflammation. It has been shown to regulate the activity of several signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. This suggests that LINC01002 may be a useful target for drugs that can modulate these pathways and prevent or reverse their pathological effects.

Biomarker Potential

LINC01002 has also been identified as a potential biomarker for several diseases. Its expression has been shown to be elevated in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that LINC01002 may be a useful biomarker for these diseases and can be used to monitor the effectiveness of therapeutic interventions.

In addition, LINC01002 has been shown to have a positive correlation with several clinical outcomes in neurodegenerative diseases, such as changes in cognitive function and clinical severity. This suggests that LINC01002 may be a useful biomarker for assessing the effectiveness of neurodegenerative disease therapies and identifying potential biomarkers for these therapies.

Methodology

To further investigate the potential drug target and biomarker properties of LINC01002, several studies have been conducted. One study identified LINC01002 as a potential drug target using its conservation sequence and its expression pattern in different tissues and cells. Another study demonstrated that LINC01002 was involved in the regulation of cellular processes that are involved in disease development, such as cell signaling and cell division.

Another study showed that LINC01002 was significantly upregulated in several neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This suggests that LINC01002 may be a useful biomarker for these diseases and can be used to monitor the effectiveness of therapeutic interventions.

Conclusion

LINC01002 is a long intergenic non-protein-coding RNA that has been identified as a potential drug target and biomarker. Its unique structure and conservation across different species suggest that it may have a similar function or structure in different organisms, which could make it an attractive target for small molecules or antibodies that can modulate its expression or activity. In addition, LINC01002 has been shown to play a role in several cellular processes that are involved in disease development, which makes it a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further studies are needed to confirm its potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1002

The "LINC01002 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01002 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets